Between PTC Therapeutics and Biogen, Which Stock Looks Set to Break Out?
Biogen surged 17% during the past Month. You may be tempted to buy more, or may want to reduce your exposure. But there is an entirely different perspective you might be missing. Is there a better alternative? Turns out, its peer PTC Therapeutics gives you more. PTC Therapeutics (PTCT) stock offers superior revenue growth across key periods, better profitability, and relatively lower valuation vs Biogen (BIIB) stock, suggesting you may be better off investing in PTCT
- PTCT’s quarterly revenue growth was 7.2%, vs. BIIB’s 2.8%.
- In addition, its Last 12 Months revenue growth came in at 97.5%, ahead of BIIB’s 4.8%.
- PTCT’s LTM margin is higher: 51.8% vs. BIIB’s 24.8%.
These differences become even clearer when you look at the financials side by side. The table highlights how BIIB’s fundamentals stack up against those of PTCT on growth, margins, momentum, and valuation multiples.
Valuation & Performance Overview
| BIIB | PTCT | Preferred | |
|---|---|---|---|
| Valuation | |||
| P/EBIT Ratio | 10.6 | 6.7 | PTCT |
| Revenue Growth | |||
| Last Quarter | 2.8% | 7.2% | PTCT |
| Last 12 Months | 4.8% | 97.5% | PTCT |
| Last 3 Year Average | -0.9% | 41.7% | PTCT |
| Operating Margins | |||
| Last 12 Months | 24.8% | 51.8% | PTCT |
| Last 3 Year Average | 22.5% | -8.9% | BIIB |
| Momentum | |||
| Last 3 Year Return | -39.7% | 86.6% | PTCT |
Note: For “Last 3 Year Return” metric, preferred stock is one with higher returns unless the returns are too high (>300%) which creates risk of sell off.
See more revenue details: BIIB Revenue Comparison | PTCT Revenue Comparison
See more margin details: BIIB Operating Income Comparison | PTCT Operating Income Comparison
See detailed fundamentals on Buy or Sell PTCT Stock and Buy or Sell BIIB Stock. Below we compare market return and related metrics across years.
Historical Market Performance
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | Avg | Best | |
|---|---|---|---|---|---|---|---|---|---|
| Returns | |||||||||
| BIIB Return | -17% | -2% | 15% | -7% | -41% | 18% | -39% | ||
| PTCT Return | 27% | -35% | -4% | -28% | 64% | 74% | 63% | ||
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 16% | 111% | <=== | |
| Monthly Win Rates [3] | |||||||||
| BIIB Win Rate | 50% | 50% | 42% | 33% | 17% | 50% | 40% | ||
| PTCT Win Rate | 58% | 33% | 58% | 42% | 83% | 60% | 56% | ||
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 70% | 64% | <=== | |
| Max Drawdowns [4] | |||||||||
| BIIB Max Drawdown | -20% | -9% | -22% | -20% | -43% | -26% | -23% | ||
| PTCT Max Drawdown | -33% | -42% | -36% | -53% | -12% | -20% | -33% | ||
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | -12% | <=== | |
[1] Cumulative total returns since the beginning of 2020
[2] 2025 data is for the year up to 12/2/2025 (YTD)
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
No matter how good the numbers, stock investment is never a smooth ride. There is a risk you must factor in. Read PTCT Dip Buyer Analyses and BIIB Dip Buyer Analyses to see how these stocks have fallen and recovered in the past.
Still not sure about BIIB or PTCT? Consider portfolio approach.
Portfolios Over Individual Stock Picks
Individual stocks are unpredictable. A smart portfolio keeps you invested, limits downside shocks, and provides upside exposure
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.